Literature DB >> 25279962

Tumor-stroma crosstalk: targeting stroma in breast cancer.

Carmen Criscitiello1, Angela Esposito, Giuseppe Curigliano.   

Abstract

PURPOSE OF REVIEW: Combinatorial strategies in cancer medicine will not only target cancer cell-intrinsic pathways, but also cancer cell-extrinsic cells, pathways, and mediators of the tumor microenvironment. The aim of the present review is to define the roles of the tumor microenvironment in primary and metastatic breast cancer progression. RECENT
FINDINGS: The cancer microenvironment is composed of nontransformed host stromal cells, such as endothelial cells, fibroblasts, various immune cells, and a complex extracellular matrix secreted by both the normal and neoplastic cells embedded in it. The stromal constituents contribute to the core and emergent hallmarks of cancer. In particular, they can boost sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, activating invasion and metastasis, reprogramming energy metabolism, and evading immune destruction.
SUMMARY: The stromal cells play a role in enabling or enhancing multiple hallmark capabilities in tumor microenvironment. This is a background for therapeutic-targeting strategies aimed to abrogate the stroma's contribution. Targeting tumor-associated fibroblasts, macrophages, angiogenesis and enhancing immune response may represent a paradigm-shifting approach to treating human cancer in the near future.

Entities:  

Mesh:

Year:  2014        PMID: 25279962     DOI: 10.1097/CCO.0000000000000122

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  20 in total

1.  Suppression of Akt1-β-catenin pathway in advanced prostate cancer promotes TGFβ1-mediated epithelial to mesenchymal transition and metastasis.

Authors:  Fei Gao; Abdulrahman Alwhaibi; Harika Sabbineni; Arti Verma; Wael Eldahshan; Payaningal R Somanath
Journal:  Cancer Lett       Date:  2017-06-07       Impact factor: 8.679

2.  Quantitative investigation of MDA-MB-231 breast cancer cell motility: dependence on epidermal growth factor concentration and its gradient.

Authors:  Tanzila Islam; Haluk Resat
Journal:  Mol Biosyst       Date:  2017-09-26

Review 3.  A tumor multicomponent targeting chemoimmune drug delivery system for reprograming the tumor microenvironment and personalized cancer therapy.

Authors:  Samaresh Sau; Katyayani Tatiparti; Hashem O Alsaab; Sushil K Kashaw; Arun K Iyer
Journal:  Drug Discov Today       Date:  2018-03-15       Impact factor: 7.851

4.  Selective isolation and characterization of primary cells from normal breast and tumors reveal plasticity of adipose derived stem cells.

Authors:  Annika Weigand; Anja M Boos; Kereshmeh Tasbihi; Justus P Beier; Paul D Dalton; Michael Schrauder; Raymund E Horch; Matthias W Beckmann; Pamela L Strissel; Reiner Strick
Journal:  Breast Cancer Res       Date:  2016-03-12       Impact factor: 6.466

5.  The Tumor Microenvironment Modulates Choline and Lipid Metabolism.

Authors:  Noriko Mori; Flonné Wildes; Tomoyo Takagi; Kristine Glunde; Zaver M Bhujwalla
Journal:  Front Oncol       Date:  2016-12-22       Impact factor: 6.244

6.  CD1a- and CD83-positive dendritic cells as prognostic markers of metastasis development in early breast cancer patients.

Authors:  Vivian Labovsky; Norma Alejandra Chasseing; María Belén Giorello; Ayelén Matas; Pablo Marenco; Kevin Mauro Davies; Francisco Raúl Borzone; María de Luján Calcagno; Hernán García-Rivello; Alejandra Wernicke; Leandro Marcelo Martinez
Journal:  Breast Cancer       Date:  2021-07-09       Impact factor: 4.239

Review 7.  Using dynamic cell communication improves treatment strategies of breast cancer.

Authors:  Zhibo Liu; Song Hu; Zehui Yun; Wanshan Hu; Shuhua Zhang; Daya Luo
Journal:  Cancer Cell Int       Date:  2021-05-25       Impact factor: 5.722

8.  Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy.

Authors:  Carly Bess Williams; Elizabeth S Yeh; Adam C Soloff
Journal:  NPJ Breast Cancer       Date:  2016-01-20

9.  Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.

Authors:  Zainab A Bazzi; Danielle Lanoue; Mouhanned El-Youssef; Rocco Romagnuolo; Janice Tubman; Dora Cavallo-Medved; Lisa A Porter; Michael B Boffa
Journal:  BMC Cancer       Date:  2016-05-24       Impact factor: 4.430

10.  Oncolytic adenovirus encoding LIGHT (TNFSF14) inhibits tumor growth via activating anti-tumor immune responses in 4T1 mouse mammary tumor model in immune competent syngeneic mice.

Authors:  Shiyun Dai; Yun Lv; Weidong Xu; Yuefeng Yang; Chao Liu; Xiwen Dong; Huan Zhang; Bellur S Prabhakar; Ajay V Maker; Prem Seth; Hua Wang
Journal:  Cancer Gene Ther       Date:  2020-04-20       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.